Study Supports Feasibility of Routine Molecular Screening of NSCLC in Community Setting
Crizotinib Active in ALK-Positive Pediatric Cancer
Oncology Leaders Praise Health Law Ruling-With Caveats
How Can We Get Better Value in End-of-Life Care?
Down the Road for Breast Cancer
Targeted Therapies to Further Improve Outcomes
How Payers and Oncologists Really Feel About Oncology Pathways
Partnering With a Payer to Develop a Value-Based Medical Home Pilot: A West Coast Practice's Experience
Oncology Patient-Centered Medical Home
Medical Drug Benefit Management in the Pathway Era
Rationalizing Treatment and Coverage Decisions With Predictive Biomarkers
Implementation of Cancer Clinical Care Pathways
Trends in the 2012 Eisai Oncology Digest: Counseling and Communication of Cancer Treatment
The Keys to Obtaining Best Value in Non-Small Cell Lung Cancer
Achieving Quality and Containing Cost Through Oncology Pharmacy Management
Treatment and Cost Implications of Pertuzumab
Michael E. Chernew, PhD; Lee N. Newcomer, MD, MHA; and Sandra M. Swain, MD; examine the treatment benefits, cost concerns, and insurance coverage strategies for pertuzumab.
